27779702|t|Extract of Caulis Spatholobi, a novel blocker targeting tumor cell ‑induced platelet aggregation, inhibits breast cancer metastasis
27779702|a|Metastasis of breast cancer is the vital step for malignant progression. During such a process, hematogenous metastasis is an indispensable approach for the dissemination of cancer cells. A platelet, contributes to hypercoagulable state, and is also identified the crucial factor in the coagulation system for supporting metastasis. Therefore, the relationship of a platelet and a tumor cell plays a critical role in tumor cell metastasis. Consequently, inhibiting tumor cell ‑induced platelet aggregation (TCIPA) is recongnized as a crucial target on suppression of tumor metastasis such as aspirin (ASA). Under such circumstance, here we report that, through dissociating the tumor‑platelet (T‑P) complex, 80% ethanol extracts of Caulis Spatholobi (SET) successfully alleviated the hypercoagulation state, thereby reducing tumor metastasis and improving the prospects of survival in breast cancer cell model. Through MTT and anti‑aggregation assay stimulated by ADP, we detected the optimum treatment time and the optimum dose of SET. By using confocal microscopy, we observed that SET can strongly block the formation of T‑P complex i n vitro. The result was further quantified and confirmed by the FACS analysis. The fluorescent value of T‑P complex was obviously decreased in the drug‑treated groups. In vivo, 4T1 cells were injected through the mouse tail vein for dynamic visualization by small animal imaging system. The metastatic intensity was quantified and the survival curve was analyzed. Additionally, general observation and hematoxylin and eosin (H&E) staining of lung tissue was performed. SET exerted an obvious effect on the inhibition of metastasis and increasing the survival rate of mice. For the molecular mechanism study of anti‑TCIPA, zymography and R T‑PCR assay preliminarily revealed the molecular mechanism of SET in the regulation of P ‑T interaction. Collectively, through drug efficacy identification and pharmacological revealing, we have obtained a promising candidate for the interference of breast metastasis by suppressing TCIPA, which will be beneficial for clinical cancer treatment.
27779702	0	28	Extract of Caulis Spatholobi	T123	C0032081
27779702	11	28	Caulis Spatholobi	T002	C0242767
27779702	38	45	blocker	T121	C1254351
27779702	56	66	tumor cell	T025	C0597032
27779702	56	96	tumor cell ‑induced platelet aggregation	T043	C0032176
27779702	107	120	breast cancer	T191	C0006142
27779702	121	131	metastasis	T191	C0027627
27779702	132	142	Metastasis	T191	C0027627
27779702	146	159	breast cancer	T191	C0006142
27779702	182	203	malignant progression	T191	C0948048
27779702	228	251	hematogenous metastasis	T191	C0027627
27779702	306	318	cancer cells	T025	C0334227
27779702	322	330	platelet	T025	C0005821
27779702	347	368	hypercoagulable state	T047	C0398623
27779702	405	411	factor	T169	C1521761
27779702	419	430	coagulation	T042	C0005778
27779702	431	437	system	T169	C0449913
27779702	453	463	metastasis	T191	C0027627
27779702	498	506	platelet	T025	C0005821
27779702	513	523	tumor cell	T025	C0597032
27779702	549	559	tumor cell	T025	C0597032
27779702	560	570	metastasis	T191	C0027627
27779702	597	607	tumor cell	T025	C0597032
27779702	597	637	tumor cell ‑induced platelet aggregation	T043	C0032176
27779702	639	644	TCIPA	T043	C0032176
27779702	684	695	suppression	T044	C1519692
27779702	699	715	tumor metastasis	T191	C0027627
27779702	724	731	aspirin	T109,T121	C0004057
27779702	733	736	ASA	T109,T121	C0004057
27779702	810	839	tumor‑platelet (T‑P) complex,	T026	C0243092
27779702	844	851	ethanol	T109,T121	C0001962
27779702	852	881	extracts of Caulis Spatholobi	T123	C0032081
27779702	864	881	Caulis Spatholobi	T002	C0242767
27779702	883	886	SET	T123	C0032081
27779702	916	938	hypercoagulation state	T047	C0398623
27779702	957	973	tumor metastasis	T191	C0027627
27779702	1005	1013	survival	T052	C0038952
27779702	1017	1023	breast	T023	C0006141
27779702	1024	1035	cancer cell	T025	C0334227
27779702	1036	1041	model	T075	C0026336
27779702	1051	1054	MTT	T059	C0201596
27779702	1059	1099	anti‑aggregation assay stimulated by ADP	T059	C0005507
27779702	1117	1139	optimum treatment time	T079	C0040223
27779702	1148	1160	optimum dose	T081	C0178602
27779702	1164	1167	SET	T123	C0032081
27779702	1178	1197	confocal microscopy	T059	C0242842
27779702	1216	1219	SET	T123	C0032081
27779702	1243	1252	formation	T169	C1522492
27779702	1256	1267	T‑P complex	T026	C0243092
27779702	1270	1277	n vitro	T080	C1533691
27779702	1334	1347	FACS analysis	T059	C0079366
27779702	1353	1370	fluorescent value	T081	C0392762
27779702	1374	1385	T‑P complex	T026	C0243092
27779702	1417	1437	drug‑treated groups.	T078	C0441833
27779702	1438	1445	In vivo	T082	C1515655
27779702	1447	1456	4T1 cells	T025	C0597032
27779702	1462	1470	injected	T061	C1533685
27779702	1483	1488	mouse	T015	C0025929
27779702	1489	1498	tail vein	T023	C2985205
27779702	1503	1524	dynamic visualization	T060	C0430022
27779702	1528	1555	small animal imaging system	T073	C2697665
27779702	1561	1581	metastatic intensity	T081	C0392762
27779702	1605	1619	survival curve	T081	C0392762
27779702	1624	1632	analyzed	T062	C0936012
27779702	1672	1708	hematoxylin and eosin (H&E) staining	T059	C0523207
27779702	1712	1716	lung	T023	C0024109
27779702	1717	1723	tissue	T024	C0040300
27779702	1739	1742	SET	T123	C0032081
27779702	1776	1786	inhibition	T052	C3463820
27779702	1790	1800	metastasis	T191	C0027627
27779702	1820	1833	survival rate	T081	C0038954
27779702	1837	1841	mice	T015	C0025929
27779702	1851	1870	molecular mechanism	T044	C1148560
27779702	1871	1876	study	T062	C2603343
27779702	1880	1890	anti‑TCIPA	T059	C0005507
27779702	1892	1902	zymography	T062	C1517469
27779702	1909	1920	T‑PCR assay	T063	C0599161
27779702	1948	1967	molecular mechanism	T044	C1148560
27779702	1971	1974	SET	T123	C0032081
27779702	1998	2012	‑T interaction	T043	C0007582
27779702	2036	2049	drug efficacy	T080	C0598333
27779702	2069	2084	pharmacological	T169	C0205464
27779702	2159	2165	breast	T023	C0006141
27779702	2166	2176	metastasis	T191	C0027627
27779702	2192	2197	TCIPA	T043	C0032176
27779702	2228	2236	clinical	T080	C0205210
27779702	2237	2253	cancer treatment	T061	C0920425